Xu Cheng Selected Research

Acids

11/2021	A sequentially responsive nanogel via Pt(IV) crosslinking for overcoming GSH-mediated platinum resistance.
10/2021	Acid-sensitive and L61-crosslinked hyaluronic acid nanogels for overcoming tumor drug-resistance.
9/2019	TPGS-grafted and acid-responsive soy protein nanogels for efficient intracellular drug release, accumulation, penetration in 3D tumor spheroids of drug-resistant cancer cells.
7/2018	Acid-degradable lactobionic acid-modified soy protein nanogels crosslinked by ortho ester linkage for efficient antitumor in vivo.
9/2017	Acid-degradable carboxymethyl chitosan nanogels via an ortho ester linkage mediated improved penetration and growth inhibition of 3-D tumor spheroids in vitro.
4/2017	3-Carboxyphenylboronic acid-modified carboxymethyl chitosan nanoparticles for improved tumor targeting and inhibitory.
9/2016	Phenylboronic acid-decorated gelatin nanoparticles for enhanced tumor targeting and penetration.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Xu Cheng Research Topics

Disease

70	Neoplasms (Cancer) 03/2024 - 09/2011
13	Non-alcoholic Fatty Liver Disease 02/2024 - 01/2019
12	Neoplasm Metastasis (Metastasis) 12/2023 - 09/2011
11	Inflammation (Inflammations) 01/2024 - 07/2015
11	Breast Neoplasms (Breast Cancer) 01/2023 - 07/2012
9	Lung Neoplasms (Lung Cancer) 03/2024 - 01/2017
9	Type 2 Diabetes Mellitus (MODY) 11/2023 - 01/2020
8	COVID-19 01/2021 - 01/2020
7	Myopia 03/2023 - 04/2016
6	Fibrosis (Cirrhosis) 12/2023 - 07/2015
5	Pain (Aches) 01/2024 - 09/2018
5	Carcinogenesis 06/2023 - 11/2003
5	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 11/2022 - 06/2014
5	Infections 08/2022 - 10/2017
5	Reperfusion Injury 01/2022 - 11/2020
4	Body Weight (Weight, Body) 01/2023 - 02/2016
4	Urinary Bladder Neoplasms (Bladder Cancer) 01/2023 - 01/2016
4	Prostatic Neoplasms (Prostate Cancer) 01/2022 - 11/2012
4	Liver Diseases (Liver Disease) 12/2021 - 01/2018
4	Cleft Lip (Harelip) 07/2019 - 01/2018
3	Hepatocellular Carcinoma (Hepatoma) 01/2024 - 12/2021
3	Colorectal Neoplasms (Colorectal Cancer) 11/2023 - 10/2013
3	Stomach Neoplasms (Stomach Cancer) 06/2023 - 02/2018
3	Adenocarcinoma of Lung 01/2023 - 01/2018
3	Cardiomegaly (Heart Hypertrophy) 01/2023 - 01/2020
3	Stroke (Strokes) 01/2023 - 01/2015
3	Myocardial Ischemia (Ischemic Heart Diseases) 01/2022 - 11/2020
3	Obesity 01/2022 - 01/2021
3	Ureteral Obstruction 01/2022 - 12/2004
3	Carcinoma (Carcinomatosis) 01/2022 - 04/2016
3	Ischemia 10/2021 - 01/2018
3	Postoperative Cognitive Complications 01/2021 - 01/2015
3	Congenital Abnormalities (Deformity) 11/2018 - 01/2018
2	Traumatic Brain Injuries (Traumatic Brain Injury) 10/2024 - 01/2023
2	Periodontitis 02/2024 - 01/2023
2	Dyslipidemias (Dyslipidemia) 12/2023 - 01/2022
2	Disease Progression 12/2023 - 01/2016
2	Liver Neoplasms (Liver Cancer) 12/2023 - 01/2017
2	Splenomegaly 12/2023 - 11/2022
2	Squamous Cell Carcinoma (Epidermoid Carcinoma) 10/2023 - 11/2022
2	Renal Cell Carcinoma (Grawitz Tumor) 01/2023 - 03/2022
2	Glioma (Gliomas) 01/2023 - 03/2011
2	Hypertrophy 01/2023 - 11/2022
2	Heart Failure 01/2023 - 10/2020

Drug/Important Bio-Agent (IBA)

16	Proteins (Proteins, Gene)FDA Link 01/2024 - 11/2003
11	Biomarkers (Surrogate Marker)IBA 01/2022 - 04/2016
10	LipidsIBA 01/2024 - 10/2013
9	EstersIBA 11/2021 - 01/2017
9	NanogelsIBA 11/2021 - 09/2017
7	AcidsIBA 11/2021 - 09/2016
7	MicellesIBA 11/2020 - 10/2015
6	Long Noncoding RNAIBA 01/2022 - 01/2018
5	RNA (Ribonucleic Acid)IBA 11/2023 - 09/2016
5	PolymersIBA 02/2023 - 10/2015
5	Messenger RNA (mRNA)IBA 01/2023 - 11/2003
5	LigandsIBA 11/2022 - 01/2017
4	Therapeutic UsesIBA 11/2023 - 09/2019
4	EnzymesIBA 01/2023 - 11/2003
4	Drug CarriersIBA 08/2021 - 01/2017
3	Glucose (Dextrose)FDA LinkGeneric 01/2024 - 01/2021
3	Phosphotransferases (Kinase)IBA 12/2023 - 01/2022
3	CytokinesIBA 11/2023 - 01/2015
3	Circular RNAIBA 06/2023 - 01/2020
3	AndrogensIBA 01/2023 - 07/2020
3	Ubiquitin-Protein Ligases (Ubiquitin-Protein Ligase)IBA 01/2022 - 01/2018
3	Competitive Endogenous RNAIBA 01/2022 - 01/2021
3	Doxorubicin (Adriamycin)FDA LinkGeneric 11/2021 - 08/2019
3	tocophersolanIBA 11/2020 - 10/2018
3	Soybean Proteins (Soy Protein)IBA 09/2019 - 01/2017
3	ElementsIBA 11/2018 - 01/2018
2	Fatty Acid Synthases (Fatty Acid Synthase)IBA 01/2024 - 11/2021
2	ChromatinIBA 01/2024 - 01/2020
2	AlbuminsIBA 12/2023 - 02/2020
2	Polysaccharides (Glycans)IBA 12/2023 - 01/2023
2	NitratesIBA 11/2023 - 01/2022
2	Pyrethrins (Pyrethroids)FDA Link 10/2023 - 09/2022
2	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 01/2023 - 01/2019
2	Carrier Proteins (Binding Protein)IBA 01/2023 - 01/2020
2	CollagenIBA 01/2023 - 02/2018
2	CholesterolIBA 01/2023 - 01/2022
2	ChitosanIBA 01/2023 - 08/2022
2	UbiquitinIBA 01/2023 - 01/2022
2	HepcidinsIBA 01/2023 - 02/2018
2	Glutathione (Reduced Glutathione)IBA 11/2022 - 11/2021
2	Type A Botulinum Toxins (Botox)FDA Link 11/2022 - 01/2021
2	thiocyanateIBA 08/2022 - 01/2022
2	Poly I-CIBA 01/2022 - 11/2020

Therapy/Procedure

32	Therapeutics 03/2024 - 11/2012
15	Drug Therapy (Chemotherapy) 01/2024 - 06/2014
7	Immunotherapy 01/2023 - 01/2021
5	Lenses 03/2023 - 12/2002
5	Radiotherapy 01/2022 - 03/2011
4	Hydrophilic Contact Lenses (Hydrophilic Contact Lens) 03/2023 - 04/2016
4	Aftercare (After-Treatment) 12/2020 - 10/2013
3	Sutures (Suture) 03/2024 - 07/2019
3	Prostatectomy (Retropubic Prostatectomy) 08/2022 - 06/2020
3	Nephrectomy 08/2017 - 01/2015
2	Operative Surgical Procedures 10/2024 - 10/2021
2	Contact Lenses 01/2023 - 01/2019
2	Adjuvant Chemotherapy 01/2022 - 07/2021